Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market
Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.
Medpage Today on MSN21h
Researchers Describe Rare Syndrome After COVID Vaccine
Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...
How do cells respond to changes? New study finds it's not all in the genes
Cells are constantly on the move, whether in a developing embryo or metastatic cancer. But how do cells adapt to the new ...